Macquarie initiated coverage of Privia Health (PRVA) with an Outperform rating and $25 price target Privia is an enduring leader aiding the transformation of the trillion-dollar healthcare industry to value-based care, the analyst tells investors in a research note. Privia has built a lasting business model that will allow it to sustain its growth momentum in the many years ahead, the firm says.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA: